Monday, March 30, 2015

Roth starts Argos Therapeutics at buy

Roth starts Argos Therapeutics at buy

March 26, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Argos Therapeutics (NASDAQ:ARGS) with a “buy” rating and $21 price target, saying the company has the potential to be one of the leaders in cancer immunotherapy. The stock closed at $8.92 on Wednesday. Argos’ proprietary technology platform, Arcelis, is based on the work of Nobel Prize-winning co-founder, […]

Roth starts Celladon at buy

Roth starts Celladon at buy

March 5, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Celladon (NASDAQ:CLDN) with a “buy” rating and 12-month price target of $70. The stock closed at $19.64 on Wednesday. Celladon is expected to announce potentially pivotal trial results from a 250-patient heart failure gene therapy trial (CUPID 2) in April 2015, writes analyst Elemer Piros. The company’s […]

Roth starts Zosano Pharma at buy

Roth starts Zosano Pharma at buy

February 23, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and price target of $20. The stock closed at $11.09 on Friday. Zosano Pharma has a microneedle “patch” platform that provides injection-like results with a more tolerable delivery vehicle. “The impetus for our buy rating is the potential of the […]

Elemer Piros joins Roth biotech team

Elemer Piros joins Roth biotech team

February 19, 2015 by · Leave a Comment 

Tweet Elemer Piros has joined Roth Capital Partners as a senior research analyst covering the biotechnology sector. Prior to joining Roth, Dr. Piros was interim CEO of eMMUNITY, an immunotherapy startup company. He was previously a senior biotechnology analyst at Rodman & Renshaw and Burrill Securities. Dr. Piros was ranked as the No. 1 biotechnology […]

Roth starts Spark Therapeutics at buy

Roth starts Spark Therapeutics at buy

February 19, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Spark Therapeutics (NASDAQ:ONCE) with a “buy” rating and 12-month price target of $71, saying Spark’s gene therapy platform could revolutionize the treatment of genetic disorders. The stock closed at $46 on Wednesday. “Spark Therapeutics, a less than two-year old company, could become the first to secure FDA […]

Roth resumes coverage of Neptune at buy

Roth resumes coverage of Neptune at buy

January 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX:NTB) with a “buy” rating and $5 price target. The stock closed at $1.83 on Thursday. Neptune is a leading provider of krill oil (omega-3 supplements) with its premium product, Neptune Krill Oil (NKO). “With a new state-of-the-art manufacturing plant, and a […]

Roth starts Titan Pharma at buy

Roth starts Titan Pharma at buy

January 20, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy rating is the potential of the company’s developmental Probuphine six-month implant of buprenorphine for the treatment of opioid dependence,” writes analyst […]

The Joint Corp. sets aggressive expansion plan

The Joint Corp. sets aggressive expansion plan

January 6, 2015 by · Leave a Comment 

Tweet Fresh from a $20-million IPO in November, The Joint Corp. (NASDAQ:JYNT), a franchisor of some 236 chiropractic clinics in 25 states, plans to more than double the number of clinics in its chain as part of a national expansion over the next five years. “Our strategy is to aggressively grow our already proven, profitable […]

Roth starts Hyperion Therapeutics at buy

Roth starts Hyperion Therapeutics at buy

November 3, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Hyperion Therapeutics (NASDAQ:HPTX) with a “buy” rating and price target of $34. The stock closed at $24.30 on Friday. “Hyperion is well positioned to expand its GI-focused rare/orphan disease franchise by leveraging key insights in the role of ammonia control in urea cycle disorders (UCD) and hepatic encephalopathy (HE),” […]

Roth names John Chambers as vice chairman

Roth names John Chambers as vice chairman

October 30, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has named John Chambers as vice chairman in addition to his ongoing role as head of healthcare investment banking, a position he has held since joining Roth 2009. Mr. Chambers and his team has assisted Roth’s healthcare clients in raising over $8-billion in approximately 220 transactions since 2009. “John is an […]

Next Page »

Email Newsletters with Constant Contact
Google+